enfatizaban

Enfatizaban is a medication that belongs to the class of beta blockers. It was being developed for the treatment of essential hypertension, which is high blood pressure in people who do not have an underlying medical condition, such as kidney disease or heart disease, that causes their high blood pressure. Enfatizaban is a selective beta-1 receptor blocker, which means it primarily targets the beta-1 receptors in the heart, causing a decrease in heart rate and myocardial contractility.

Enfatizaban was being developed in Japan and was licensed for clinical trials by Mochida Pharmaceutical Co. Ltd. The development of enfatizaban was stopped in 2008 due to lack of a substantial therapeutic effect. Further research and clinical trials did not demonstrate that the potential benefits of enfatizaban outweighed the potential risks. However, studies in animals have shown that enfatizaban has effects that suggest it could be used to treat certain conditions such as vasodilation.

Beta blockers like enfatizaban are typically contraindicated in patients with certain medical conditions, such as asthma, or those with a history of certain conditions, such as heart block. Patients with severe bradycardia (abnormally slow heart rate) or heart failure should be closely monitored while taking beta blockers. Additionally, patients should inform their doctor about any allergies or sensitivities they may have to the drug or its inactive ingredients.

No existing research was found on the safety of taking enfatizaban during pregnancy or breastfeeding. Patients who are pregnant or breastfeeding should discuss the potential risks and benefits of the drug with their doctor before taking it. The U.S. FDA and other regulatory bodies did not review the safety or effectiveness of enfatizaban as of its last available data.